[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-urinary-tract-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-urinary-tract-symptoms":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,42,72,91,118,149,174,210,237,266,288,321,347,369,398,426,447,485,507,517,541,558,580,601,622],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053550","holep-prior-to-radiation-therapy-for-patients-with-lutsretention-and-concurrent-prostate-cancer-100053550",false,"NCT03802851","HoLEP Prior to Radiation Therapy for Patients With LUTS\u002FRetention and Concurrent Prostate Cancer","HOLEP-RTPC","Inclusion Criteria:\n\n* Patients must be 18 years of age or older\n* Patients must have bothersome lower urinary tract symptoms (LUTS), defined by American Urological Association Symptom Score (AUA SS) of greater than or equal to 15 and\u002For as defined by a post-void residual of greater than or equal to 350mL and\u002For as defined by catheter dependence\n* Patients must be diagnosed with prostate cancer by pathological tissue analysis\n* Patients must have elected for radiation with androgen deprivation therapy as the primary treatment modality for their prostate cancer\n\nExclusion Criteria:\n\n* Patients who are under 18 years of age are not eligible\n* Patients who have a diagnosis of bladder cancer are not eligible.\n* Patients with prior treatment for prostate cancer are not eligible.\n* Patients with any type of prior prostate surgery (minimally invasive, endoscopic, or otherwise) including prior transurethral resection of the prostate (but excluding prior prostate biopsy) are ineligible.\n* Patients with known metastatic prostate cancer are ineligible\n* Patients who are enrolled in other surgical or international trials at the time of this study are not eligible","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and\u002For urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.",[27,28],"Prostate Cancer","Lower Urinary Tract Symptoms","RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2019-09-19",{"date":37,"type":21},"2035-01",{"name":39,"class":40},"University of Kansas Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100642693","water-vapor-thermal-therapy-versus-ejaculation-sparing-bipolar-transurethral-enucleation-for-benign-prostatic-hyperplasia-100642693","NCT07648888","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","REZ-ESBTUEP","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) 15 mL\u002Fs or less with voided volume 150 mL or more.\n* Post-void residual urine volume 250 mL or less.\n* Failed, intolerant, or unwilling to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Recurrent urinary retention or suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.","MALE","50 Years",{"count":53,"type":21},120,[24],"This prospective comparative study will evaluate Water Vapor Thermal Therapy (WVTT\u002FRezum) versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate (ES-B-TUEP) in sexually active men with symptomatic benign prostatic hyperplasia.\n\nEligible patients will have moderate-to-severe lower urinary tract symptoms, preserved antegrade ejaculation at baseline, and will be candidates for procedural treatment after failure, intolerance, or unwillingness to continue medical therapy. This is not a randomized study. Treatment selection will be based on shared decision-making between the patient and the treating surgeon after standardized counseling about both procedures.\n\nThe study will compare ejaculatory function, urinary symptom improvement, urinary flow, post-void residual urine, erectile function, perioperative outcomes, complications, catheterization duration, hospital stay, medication restart, and retreatment or reintervention during follow-up. The primary outcome will be the change in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form Function domain score from baseline to 12 months.",[57,28,58],"Benign Prostatic Hyperplasia","Ejaculatory Dysfunction",[60,61,62],"Water Vapor Thermal Therapy","Ejaculation-Sparing","MSHQ-EjD-SF","2026-06-10",{"date":65,"type":33},"2026-06-15",{"date":67,"type":33},"2026-06-08",{"date":69,"type":21},"2027-12",{"name":71,"class":40},"Beni-Suef University",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":90,"locationsCount":41},"100641924","water-vapor-thermal-therapy-versus-ejaculation-preserving-holep-for-benign-prostatic-hyperplasia-100641924","NCT07648875","Water Vapor Thermal Therapy Versus Ejaculation-Preserving HoLEP for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Preserving Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) of 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) of 15 mL\u002Fs or less with voided volume of at least 150 mL.\n* Post-void residual urine volume of 250 mL or less.\n* Failure, intolerance, or unwillingness to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.",{"count":53,"type":21},[24],"This prospective comparative study will evaluate Water Vapor Thermal Therapy (Rezum) versus ejaculation-preserving Holmium Laser Enucleation of the Prostate (EP-HoLEP) in sexually active men with symptomatic benign prostatic hyperplasia and prostate volume 30-80 mL.\n\nEligible patients will not be randomized. The treatment option will be selected through shared decision-making between the patient and treating physician after standardized counseling about the expected benefits, risks, recovery, catheter duration, urinary outcomes, durability, and potential effects on ejaculation and sexual function.\n\nThe main objective is to compare the change in ejaculatory function from baseline to 12 months using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Function domain. Secondary outcomes will include urinary symptom improvement, quality of life, maximum urinary flow rate, post-void residual urine volume, erectile function, antegrade ejaculation preservation, catheterization duration, hospital stay, complications, restart of benign prostatic hyperplasia medication, and retreatment or reintervention within 12 months.",[57,28],[60,84,85,86],"Rezum","Ejaculation-Preserving HoLEP","Male Sexual Health Questionnaire",{"date":65,"type":33},{"date":67,"type":33},{"date":69,"type":21},{"name":71,"class":40},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":41},"100640142","ejaculation-preserving-versus-standard-bipolar-tuep-for-bph-100640142","NCT07629479","Ejaculation-Preserving Versus Standard Bipolar TUEP for BPH","Bipolar Transurethral Enucleation of the Prostate With Preservation of Ejaculation in Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Trial","EP-BTUEP","Inclusion Criteria:\n\n* Male patients with lower urinary tract symptoms secondary to benign prostatic obstruction after failed medical treatment for at least 3 months.\n* Sexually active patients with a continuous relationship with the same partner.\n* International Prostate Symptom Score of 8 or greater.\n* Transrectal ultrasound-estimated prostate size between 40 and 100 cc.\n* Eligible for bipolar transurethral enucleation of the prostate.\n* Ability to complete the required sexual and urinary function questionnaires.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative sexual dysfunction.\n* Preoperative ejaculatory dysfunction.\n* Diagnosis or suspicion of prostate cancer.\n* Neurological disorders affecting lower urinary tract or sexual function.\n* Detrusor hypocontractility.\n* Catheter-dependent patients.\n* Patients with bladder stones.\n* Inability or refusal to provide informed consent.",{"count":100,"type":21},60,[24],"This prospective randomized controlled trial will compare ejaculation-preserving bipolar transurethral enucleation of the prostate with standard bipolar transurethral enucleation of the prostate in sexually active men with benign prostatic hyperplasia and lower urinary tract symptoms after failed medical treatment. Participants will be randomly assigned to either ejaculation-preserving B-TUEP or standard B-TUEP. The study will evaluate preservation of ejaculatory function, erectile function, urinary symptom improvement, uroflowmetry outcomes, post-void residual urine, perioperative complications, and need for retreatment during follow-up.",[57,28,104],"Benign Prostatic Obstruction",[106,107,108,109],"Bipolar transurethral enucleation of the prostate","B-TUEP","Ejaculation preservation","International Prostate Symptom Score","2026-06-01",{"date":112,"type":33},"2026-06-05",{"date":114,"type":33},"2025-09-08",{"date":116,"type":21},"2026-09",{"name":71,"class":40},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":41},"100637967","phase-2-melatonin-and-solifenacin-for-double-j-ureteral-stent-symptoms-100637967","NCT07617922","Melatonin and Solifenacin for Double-J Ureteral Stent Symptoms","Melatonin Versus Solifenacin Versus Their Combination for Improving Double-J Ureteral Stent-Related Symptoms and Quality of Life: A Prospective Randomized Study","MEL-SOL-STENT","Inclusion Criteria:\n\n1. Age 18 to 60 years.\n2. Patients undergoing unilateral ureteroscopy or ureteroscopic lithotripsy with insertion of a unilateral Double-J ureteral stent.\n3. Ability to understand and complete the study questionnaires.\n4. Willingness to participate and provide written informed consent.\n\nExclusion Criteria:\n\n1. Bilateral ureteral stents.\n2. Stents inserted for malignant ureteral obstruction or non-stone reconstructive indications.\n3. Known hypersensitivity or contraindication to solifenacin or melatonin.\n4. History of acute or chronic urinary retention, or evidence of clinically significant bladder outlet obstruction at baseline.\n5. History of narrow-angle glaucoma or other contraindications to antimuscarinic therapy, including gastric retention.\n6. Significant hepatic impairment.\n7. Severe renal impairment if judged clinically relevant to study medication safety.\n8. Pre-existing moderate to severe lower urinary tract symptoms unrelated to the stent.\n9. Recent use of antimuscarinics, alpha-blockers, or melatonin that may interfere with symptom assessment.\n10. Pregnancy or lactation.\n11. Inability to complete follow-up.","60 Years",{"count":128,"type":21},189,[130],"PHASE2","Double-J ureteral stents are commonly inserted after ureteroscopy, but they may cause bothersome urinary symptoms, pain, sleep disturbance, and reduced quality of life.\n\nThis prospective randomized assessor-blinded three-arm clinical trial will compare oral solifenacin, oral melatonin, and their combination for improving ureteral stent-related symptoms in adult patients after unilateral ureteroscopic lithotripsy with insertion of a unilateral Double-J ureteral stent.\n\nParticipants will be randomized to receive solifenacin 5 mg once daily, melatonin 3 mg once nightly, or combined solifenacin 5 mg once daily plus melatonin 3 mg once nightly for 14 days after surgery. The primary outcome is the total Ureteral Stent Symptom Questionnaire score at postoperative Day 7. Secondary outcomes include total Ureteral Stent Symptom Questionnaire score at Day 14, change in questionnaire score between Day 7 and Day 14, Insomnia Severity Index score, Visual Analogue Scale pain score, adverse events, treatment compliance, and rescue analgesic consumption.",[133,134,28],"Ureteral Stent-Related Symptoms","Ureteral Calculi",[136,137,138,139,140],"Double-J ureteral stent","Ureteral stent symptoms","Ureteral Stent Symptom Questionnaire","Solifenacin","Melatonin","2026-05-29",{"date":143,"type":33},"2026-06-02",{"date":145,"type":33},"2026-05-07",{"date":147,"type":21},"2027-05",{"name":71,"class":40},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":158,"studyType":159,"phases":4,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100480992","bph-global-registry-100480992","NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH",{"count":157,"type":21},7500,"3 Years","OBSERVATIONAL","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[57,28],[163],"BPH, Registry, LUTS","2026-04-21",{"date":166,"type":33},"2026-04-24",{"date":168,"type":33},"2023-03-13",{"date":170,"type":21},"2027-03",{"name":172,"class":40},"Société Internationale d'Urologie",26,{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":181,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":186,"conditions":187,"keywords":195,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100634125","the-voided-urinary-perineal-and-faecal-microbiota-among-children-and-adolescents---the-ppuf-study-100634125","NCT07535619","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents - the PpUF-study.","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children and Adolescents - the PpUF-study.","Inclusion Criteria:\n\n* Overactive bladder as per International Children's Continence Society criteria (cases only).\n* At least two wet days per week (cases only).\n* No prior pharmacological treatment of OAB and DUI (cases only).\n* No lower urinary tract symptoms (healthy participants only).\n* Negative urine dipstick test\n\nExclusion Criteria:\n\n* No known urogenital abnormality affecting the lower urinary tract function.\n* No known gastrointestinal or neurological diseases.\n* No use of systemic drugs within five half-lives of the drug.\n* No use of systemic antibiotics within three months before inclusion\n* No current urinary tract infection.\n* No urinary tract infection within the last three months prior to inclusion.\n* No current constipation.\n* Abnormal uroflowmetry (healthy participants only).",true,"5 Years","17 Years",{"count":185,"type":21},110,"The aim of this study is to investigate whether the voided urinary, perineal\u002Fpreputial, and the fecal microbiota are different between children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the study aims to investigate if the microbiota is different according to the severity of DUI and if the microbiota is changed throughout treatment of DUI. A follow-up study will as well be performed on healthy children to investigate how the microbiota evolves with increasing age and pubertal stage. Children with OAB and DUI will be recruited from involved pediatric departments, and specimen in the form of urine, perineal\u002Fpreputial swabs, and feces will be collected according to the protocol.",[188,189,190,191,28,192,193,194],"Urinary Incontinence","Daytime Wetting","Urination Disorders","Urologic Diseases","Urological Manifestations","Elimination Disorders","Behavioral Symptoms",[196,197,198,199],"Voided Urinary Microbiota","Perineal Microbiota","Fecal Microbiota","Illumina MiSeq Sequencing","2026-04-15",{"date":202,"type":33},"2026-04-17",{"date":204,"type":33},"2022-12-14",{"date":206,"type":21},"2028-06",{"name":208,"class":40},"Aalborg University Hospital",4,{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":181,"sex":17,"minAge":217,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":226,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":209},"100515295","brain-activity-among-children-with-overactive-bladder-and-daytime-urinary-incontinence-and-healthy-children-100515295","NCT05989646","Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children","Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children, and Modulation of Brain Activity by Transcutaneous Electrical Nerve Stimulation - a Functional Magnetic Resonance Imaging Study","Inclusion Criteria:\n\n* Overactive Bladder as per International Children's Continence Society criteria (cases only).\n* At least 2 incontinence episodes per week (cases only).\n* No urinary tract symptoms (healthy participants only).\n* More than 3 daily urinations.\n* Normal clinical examination.\n\nExclusion Criteria:\n\n* Known urogenital abnormality affecting the lower urinary tract function.\n* Prior surgery in the urinary tract (except circumcision).\n* Known neurological diseases or prior cerebral surgery.\n* Known neuropsychiatric disorders or suspicion of those by screening.\n* Treatment with pharmacological agents affecting the brain function.\n* Prior treatment with Enuresis Alarm or Transcutaneous Electrical Nerve Stimulation.\n* Prior or current treatment with mirabegron or oxybutynin.\n* Current urinary tract infection.\n* Current constipation according to Rome IV-criteria or faecal incontinence.\n* Claustrophobia.\n* Metallic items in the body contraindicating MRI-scans.\n* Abnormal uroflowmetry (healthy participants only).","6 Years","14 Years",{"count":220,"type":21},65,[24],"The aim of this study is to investigate whether the activity in brain areas controlling the bladder is different among children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the aim is to investigate if sacral transcutaneous electric nerve stimulation (TENS) has a central mechanism of action. Children with OAB and DUI will be recruited from involved pediatric departments, and functional magnetic resonance imaging (fMRI) will be performed before and after 10 weeks of sacral TENS. In healthy children without bladder symptoms, only the baseline fMRI will be performed.",[188,189,190,224,191,28,192,194,225,193],"Urination Involuntary","Mental Disorders",[227,228,229,230],"Transcutaneous Electrical Nerve Stimulation","TENS","Functional Magnetic Resonance Imaging","fMRI",{"date":232,"type":33},"2026-04-20",{"date":234,"type":33},"2021-05-05",{"date":69,"type":21},{"name":208,"class":40},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":41},"100628876","phase-4-silodosin-vs-tamsulosin-for-luts-due-to-bph-a-randomized-crossover-trial-100628876","NCT07467343","Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial",": Efficacy of Silodosin Versus Tamsulosin in Patients With Moderate to Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Randomized Crossover Clinical Trial","Inclusion Criteria:\n\n* Male participants aged 50 years or older\n* Diagnosis of benign prostatic hyperplasia with moderate to severe lower urinary tract symptoms\n* International Prostate Symptom Score of 8 or greater\n* Prostate volume of 30 mL or greater\n* Able and willing to provide informed consent\n* No active treatment for benign prostatic hyperplasia during the month before enrollment\n\nExclusion Criteria:\n\n* Suspected neurogenic bladder\n* Bladder neck contracture\n* Urethral stricture\n* Chronic urinary retention\n* Prostate cancer\n* Urinary bladder stones\n* Urinary bladder tumors\n* History of prostate surgery\n* Known allergy, hypersensitivity, or contraindication to silodosin or tamsulosin\n* Current use of alpha-adrenergic blocker therapy\n* Severe renal impairment with creatinine clearance less than 30 mL\u002Fmin\n* Severe hepatic impairment\n* Concomitant use of strong cytochrome P450 3A4 inhibitors, including ketoconazole, clarithromycin, itraconazole, or ritonavir",{"count":245,"type":21},140,[247],"PHASE4","The goal of this randomized crossover clinical trial is to compare the efficacy and safety of Silodosin versus Tamsulosin in patients with moderate to severe lower urinary tract symptoms due to Benign Prostatic Hyperplasia. The main questions it aims to answer are:\n\nDoes Silodosin provide superior improvement in symptom scores (IPSS) compared to Tamsulosin?\n\nIs there a difference in safety profile and adverse events between the two treatments?\n\nResearchers will compare both treatments in a crossover design, where each participant receives both medications in different periods without a washout phase, to evaluate individual response differences.\n\nParticipants will:\n\nReceive both study medications in different periods according to random allocation.\n\nUndergo periodic assessment of urinary symptoms and quality of life.\n\nPerform routine follow-up evaluations including symptom scoring and urine flow measurements.",[57,28],[251,252,253,57,28,109,254,255],"Silodosin","Tamsulosin","Alpha-1 Adrenergic Antagonists","Uroflowmetry","Postvoid Residual Urine","NOT_YET_RECRUITING","2026-03-12",{"date":259,"type":33},"2026-03-16",{"date":261,"type":21},"2026-03-22",{"date":263,"type":21},"2026-10-22",{"name":265,"class":40},"Ain Shams University",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":50,"minAge":4,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":41},"100588970","phase-2-rada16-for-aquablation-day-case-100588970","NCT06948331","RADA16 for Aquablation Day Case","A Pilot Proof of Concept Single-arm Study Using PuraStat Following the Aquablation Procedure to Assess Reduction of Hematuria to Allow for Same Day Discharge","RAD","Inclusion Criteria:\n\n• Any man undergoing Aquablation for LUTS due to BPH\n\nExclusion Criteria:\n\n• Unwilling to sign consent",{"count":7,"type":21},[130],"This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge.\n\nThe primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation.\n\nThe secondary objective is to assess the number of patients discharged on the same day based on the hematuria criteria (Grade 0 and Grade I).",[278,57,28],"Hematuria","2026-02-25",{"date":281,"type":33},"2026-02-27",{"date":283,"type":21},"2026-04-01",{"date":285,"type":21},"2026-08-01",{"name":287,"class":40},"NYU Langone Health",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":181,"sex":17,"minAge":126,"maxAge":4,"enrollmentInfo":296,"targetDuration":158,"studyType":159,"phases":4,"briefSummary":298,"conditions":299,"keywords":306,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":41},"100620445","urinary-function-and-multimorbidity-risks-a-longitudinal-study-in-beijing-community-dwelling-elderly-100620445","NCT07357714","Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling Elderly","Longitudinal Study on Urinary Function and Multimorbidity Risks Among Beijing Community-dwelling Elderly UFMR-BCE Longitudinal Study","UFMR-BE","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Permanent resident of the participating Beijing community\n* Able to cooperate with and complete study questionnaires and related procedures\n\nExclusion Criteria:\n\n* Severe mental illness that impairs ability to cooperate with the study\n* End-stage disease (confirmed by clinical diagnosis)\n* Clinically assessed life expectancy \\\u003C 1 year",{"count":297,"type":21},500,"This study focuses on Beijing community residents aged 60 and above, aiming to understand how urinary function (like bladder or kidney function) and multiple health problems (such as high blood pressure, diabetes) affect each other as people age-since current studies often only look at single diseases and don't cover this group well. To join, participants need to be a 60+ Beijing community resident who can answer simple questions; those with serious mental illnesses or expected lifespan under 1 year can't take part. The study starts with a baseline check (asking about the participants' health, habits, doing blood\u002Furine tests or urinary function assessments, and possibly collecting small blood\u002Furine samples). After that, the investigators will follow up every 6-12 months (via phone or clinic to update health info) and repeat key checks yearly; people with lower cognitive ability will be checked every 3 months. The investigators will also record new illnesses, mobility issues (like falls), or death. The study has passed ethical review-participants will get clear info before joining, can quit anytime, and participants' data will stay private; participants will also get free health check reports and basic advice. For participants, this means regular health monitoring; for everyone, it'll help make tools to spot high-risk groups (like a community app), design better help (e.g., exercise plans), and push for yearly urinary health checks in communities.",[300,301,57,302,28,303,304,305],"Chronic Kidney Disease","Overactive Bladder","Female Pelvic Floor Dysfunction","Metabolic Syndrome","Cardiovascular Diseases","Diabetes Mellitus",[307,308,309,310,311],"Beijing community-dwelling elderly","Urinary function","Multimorbidity","Longitudinal study","Age-related functional decline","2026-01-13",{"date":314,"type":33},"2026-01-22",{"date":316,"type":21},"2026-01-01",{"date":318,"type":21},"2028-12-31",{"name":320,"class":40},"Chinese PLA General Hospital",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":50,"minAge":329,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":345,"locationsCount":41},"100616622","phase-4-intermittent-vs-daily-tamsulosin-for-lutsbph-100616622","NCT07308002","Intermittent vs Daily Tamsulosin for LUTS\u002FBPH","Intermittent (Every-Other-Day) vs Daily Tamsulosin for Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (LUTS\u002FBPH) : A Multicenter, Assessor-Blinded, Randomized Non-Inferiority Trial. Arab Randomized Assessment of BPH Treatment (ARAB Trial)","ARAB","Inclusion Criteria:\n\n* • Men ≥40 years with LUTS\u002FBPH.\n\n  * IPSS ≥8, Qmax 5-15 mL\u002Fs (voided volume ≥150 mL), PVR \\\u003C200 mL.\n  * Sexually active within the past month (for ejaculatory outcomes).\n  * BPH-treatment naïve: no prior use of antimuscarinics or 5-α-reductase inhibitors (5-ARIs) and agrees not to initiate these agents during the trial.\n\nExclusion Criteria:\n\n* • PVR ≥ 200 mL.\n\n  * Prior prostate\u002F radical pelvic surgery (that affect pelvic innervation).\n  * Neurogenic bladder (atonic\u002F hypotonic bladder).\n  * Severe hepatic\u002Frenal insufficiency.\n  * Significant cardiovascular or cerebrovascular disease.\n  * Any indication of surgical treatment (vesical stones, chronic urine retention, recurrent attacks of acute urine retention, recurrent attacks of gross hematuria, hydronephrosis)","40 Years",{"count":331,"type":21},288,[247],"Background:\n\nLower urinary tract symptoms (LUTS) are common in aging men, most often due to benign prostatic hyperplasia (BPH), and significantly impair quality of life. α1-adrenoceptor antagonists are first-line therapy, with tamsulosin being the most widely prescribed. However, ejaculatory dysfunction (EjD) is a frequent adverse effect that negatively affects adherence. Optimal dosing strategies that maintain urinary efficacy while reducing EjD are not well defined, and current guidelines provide no recommendations regarding alternate-day dosing.\n\nPatients and Methods:\n\nThis multicenter, randomized, open-label, assessor-blinded, parallel-group, non-inferiority trial will enroll men aged ≥50 years with LUTS\u002FBPH and baseline IPSS ≥8. Participants will be randomized 1:1 to receive tamsulosin 0.4 mg once daily or every other day for 24 weeks. The primary endpoint is change in International Prostate Symptom Score (IPSS) from baseline to Week 24. Non-inferiority will be concluded if the upper bound of the two-sided 95% confidence interval (CI) for the between-group difference in mean IPSS change (EOD - Daily) is ≤ +3 points.\n\nThe key secondary endpoint is change in Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD) total score from baseline to Week 24, tested for superiority only if IPSS non-inferiority is established. Additional secondary endpoints include maximum urinary flow rate (Qmax), post-void residual volume (PVR), IPSS-Quality of Life score, and ejaculatory adverse-event rates.\n\nSample Size and Analysis:\n\nAssuming an SD of 6 for IPSS change, a non-inferiority margin of +3, one-sided α of 0.025, and 90% power, approximately 85 evaluable patients per arm are required for the primary endpoint. To ensure adequate power for EjD outcomes and allow for 20% attrition, 144 participants per arm (288 total) will be randomized. Analyses will follow the intention-to-treat principle with per-protocol sensitivity analyses. Primary inference will use ANCOVA or MMRM adjusted for baseline score, age, and study site, with multiple imputation for missing data.\n\nExpected Outcomes:\n\nThis trial will provide the first adequately powered multicenter evidence on whether every-other-day tamsulosin preserves non-inferior LUTS control while improving ejaculatory outcomes, potentially supporting a simple and cost-effective strategy to enhance tolerability and adherence in men with LUTS\u002FBPH.",[28,335],"Prostate Obstruction",[28,252,337,338,58],"Benign prostatic obstruction","Alternate-Day Dosing","2025-12-19",{"date":341,"type":33},"2025-12-29",{"date":316,"type":21},{"date":344,"type":21},"2027-02-01",{"name":346,"class":40},"Mansoura University",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":181,"sex":50,"minAge":18,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":41},"100540919","us-imaging-for-the-assessment-of-luts-100540919","NCT06323109","US Imaging for the Assessment of LUTS","Ultrasound Imaging for the Assessment of Lower Urinary Tract Symptoms","Inclusion Criteria: Patients with BPH\u002FLUTS\n\n* Age 18-80 years old\n* Diagnosed with BPH\u002FLUTS with or without obstruction\n\nExclusion Criteria:\n\n* Patients with contraindication to MRI and\u002For GBCA contrast agent. Diabetic subjects will not receive contrast.\n* History of overt neurologic disease other than diabetic neuropathy, urinary tract infection within the last 4 weeks or recent history of urinary retention (within the last 4 weeks).\n\nInclusion Criteria: Healthy Volunteers\n\n\\- Age 18-80 years old not experiencing any symptoms consistent with LUTS\n\nExclusion Criteria:\n\n* Patients with contraindication to MRI and\u002For GBCA contrast agent.\n* Currently taking medications with known effects on the bladder, overt neurologic disease other than diabetic neuropathy, urinary tract infection within the last 4 weeks or urinary retention symptoms.","80 Years",{"count":356,"type":21},80,"The purpose of this research is to develop an ultrasound (US) based urodynamics (UDS) evaluation of voiding based on successful magnetic resonance imaging (MRI)-UDS evaluation. Both US and MRI are non-invasive imaging techniques, but US is a more cost-effective and widely available technology. 80 participants will be enrolled and will be on study for up to 2.5 hours (1.5 hour MRI and 1 hour US).",[28,359],"BPH","2025-12-18",{"date":362,"type":33},"2025-12-22",{"date":364,"type":33},"2023-11-28",{"date":366,"type":21},"2027-01",{"name":368,"class":40},"University of Wisconsin, Madison",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":41},"100406534","transcutaneous-tibial-neuro-stimulation-to-improve-voiding-dysfunction-in-multiple-sclerosis-100406534","NCT04573673","Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis.","Efficacy and Safety of Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis Patients.","NEUROSTIM-SEP1","Inclusion Criteria:\n\n* Patient with a diagnosis of multiple sclerosis\n* Patient with bladder-sphincter dyssinergia\n* Patient using clean intermittent self-catheterization as exclusive bladder management\n* Patient who has given written consent\n* Socially insured patient\n* Patient willing to comply with all study procedures and study duration\n\nExclusion Criteria:\n\n* Patient with other associated neurological pathology\n* Patient with an Expanded Disability Status Scale (EDSS) score ≥ 6\n* Patient with recurrent urinary tract infections (\\> 3 episodes \u002F year)\n* Patient with uncontrolled overactive bladder\n* Patient with uncontrolled detrusor hyperactivity\n* Patient with a bladder compliance disorder\n* Patient with tibial neuro-stimulation in the last 3 months\n* Patient treated with a sacral neuro-modulation\n* Patient who has received an intradermal injection of botulinum toxin A within the last 9 -months Patient who received alpha-blocker treatment within the last month Patient with benign prostatic hypertrophy (prostate volume \\> 40 cc) - Last ultrasound scan \\\u003C 6 months.\n\nPatient with one or more bladder diverticulum(s) Patient with unilateral or bilateral renal Patient with unilateral or bilateral vesico-ureteral reflux Patient with impaired renal function (GFR according to CKD-EPI \\\u003C 60 ml\u002Fmin\u002F1.73m2) Patient with a metallic prosthesis on the lower limb Patient with a Pacemaker Pregnant patient","65 Years",{"count":379,"type":21},68,[24],"The present trial is designed to assess the efficacy and safety of transcutaneous tibial neuro-stimulation (TTNS) in improving bladder emptying in multiple sclerosis (MS) patients.\n\nPatients presenting with MS and performing clean intermittent self-catheterization (CISC) to empty the bladder in the context of voiding dysfunction, will be eligible.\n\nIncluded patients will be randomly assigned to two distinct arms\n\n* PTNS de verum : patients will be treated with transcutaneous tibial neuro-stimulation at a rate of one session of 30 consecutive minutes daily for a period of 12 weeks.\n* PTNS placebo : Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for a period of 12 weeks (same treatment regimen as the experimental group).\n\nEfficacy in improving voiding dysfunction will be assessed 12 weeks after randomization using the BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume \u002F total bladder volume.",[383,28],"Multiple Sclerosis",[385,386,387,388],"Multiple sclerosis","Voiding dysfunction","Bladder-sphincter dyssinergia","Tibial neuro-stimulation","2025-12-16",{"date":391,"type":33},"2025-12-23",{"date":393,"type":33},"2021-12-01",{"date":395,"type":21},"2026-06",{"name":397,"class":40},"University Hospital, Lille",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":414,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":41},"100384647","5-alpha-reductase-2-as-a-marker-of-resistance-to-5ari-therapy-100384647","NCT04288427","5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy","Inclusion Criteria:\n\n* Male (physiological);\n* Age ≥ 50;\n* Eligible for treatment with 5ARI therapy;\n* Presence of lower urinary tract symptoms secondary to BPH;\n* Prostate size \\>40cc by digital rectal examination;\n* Absence of prostate nodule, tenderness or firmness;\n* Mildly elevated PSA's \\>1.5 ng\u002Fml and ≤ 40 ng\u002Fml;\n* Undergoing clinically indicated prostate biopsy for elevated prostate-specific antigen (PSA).\n\nExclusion Criteria:\n\n* Diagnosis of any prostatic malignancy or precancerous lesions (atypical glandular foci and prostatic intraepithelial neoplasia);\n* Treatment with 5ARI (Finasteride or Dutasteride) within six months of study enrollment;\n* Current urinary tract infection;\n* Previous pelvic radiation;\n* Previous treatment with demethylating drugs;\n* Diagnosis of multiple sclerosis, Alzheimer's, Parkinson's, neurological deficits in the judgment of the investigator;\n* Unable or unwilling to undergo MRI due to implants, claustrophobia, etc.",{"count":53,"type":21},[24],"The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.",[57,408,409,410,411,28,412,413],"Prostate Hyperplasia","Prostate Disease","Prostate Hypertrophy","Prostate Pain","Urinary Obstruction","Urinary Tract Disease",[415,416],"Finasteride","5 Alpha Reductase","2025-10-27",{"date":419,"type":33},"2025-10-28",{"date":421,"type":33},"2020-09-25",{"date":423,"type":21},"2026-11-30",{"name":425,"class":40},"Beth Israel Deaconess Medical Center",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":181,"sex":50,"minAge":329,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":41},"100543197","status-of-disease-burden-of-lower-urinary-tract-symptoms-in-chinese-male-community-100543197","NCT06352736","Status of Disease Burden of Lower Urinary Tract Symptoms in Chinese Male Community","Inclusion Criteria:\n\n1. Mainland China, aged 40 or older, male, in 31 provincial-level administrative regions.\n2. Have resided for a total of 6 months or more in the survey county (district) in the past 12 months.\n3. Normal communication, cooperation during physical examination, and good cognitive ability.\n4. Willing to participate in and cooperate with this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Closed communities, such as armed forces and nursing homes.\n2. Individuals with mental illnesses or other conditions that prevent cooperation.",{"count":433,"type":21},12567,"This study, set up as a cross-sectional survey, seeks to delve into the disease burden and the demographic specifics of lower urinary tract symptoms (LUTS) among the male community in China. The investigators's main aim is to map out the overall and age-specific prevalence rates of LUTS within the Chinese male population. These insights are critical for understanding the public health dimensions of this condition. Moreover, the investigators plan to investigate several secondary aspects: the correlation of LUTS prevalence with factors like urbanization levels (rural vs. urban), geographical distribution, and lifestyle choices. Another significant focus will involve examining the treatment landscape for LUTS, looking at the portion of sufferers receiving treatment, the diversity in treatment durations, and the types of treatments employed (medication vs. surgery). This comprehensive analysis is intended to shed light on the prevailing management strategies for LUTS in China. The study is scheduled to unfold over 36 months and will comprise three pivotal phases: initial preparations, recruitment of subjects and collection of data, followed by the analysis of data and compilation of reports. The investigators will employ a range of methods such as questionnaires, physical exams, laboratory tests, imaging, and other medical evaluations to amass extensive data. This will allow the investigators to evaluate the prevalence of LUTS across various age groups among men and address the current gaps in epidemiological understanding.",[28],[28,437,438],"Chinese community male population","Prevalence rate","2025-09-22",{"date":441,"type":33},"2025-09-25",{"date":443,"type":33},"2023-06-01",{"date":445,"type":21},"2026-12-31",{"name":320,"class":40},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":181,"sex":453,"minAge":18,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":457,"conditions":458,"keywords":466,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":41},"100606457","pelvic-floor-disorder-symptoms-in-women-seeking-weight-loss-therapy-100606457","NCT07175805","Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy","Inclusion Criteria:\n\n* female\n* 18-89 years old\n* any race\u002Fethnicity\n* BMI ≥30 kg\u002Fm2\n* current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic \\& Bariatric Surgery\n* able\u002Fwilling to give informed consent\n* have a home scale to measure weight\n\nPatients meeting all the following criteria will be eligible to participate in the medical weight loss therapy arm:\n\n* prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1\u002Fgastric inhibitory peptide (GIP1)\n* taking other weight loss agents (such as metformin)\n\nPatients meeting all the following criteria will be eligible to participate in the bariatric surgery arm:\n\n* plan to undergo gastric sleeve or gastric bypass surgery\n* taking weight loss agents which are not GLP-1 RA or GLP-1\u002FGIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1\u002FGIP1 medications after surgery.\n\nExclusion Criteria:\n\n* Pregnant\n* ≥90 years old\n* \\\u003C18 years old\n* BMI \\\u003C30 kg\u002Fm2\n* A history of bariatric surgery prior to enrollment\n* No home scale to measure weight\n* Active cancer","FEMALE","90 Years",{"count":456,"type":21},200,"The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss. Examples of pelvic floor symptoms include urinary incontinence, urinary urgency, urinary frequency, fecal incontinence, and vaginal prolapse. Participants in this study do not need to have any pelvic floor symptoms to enroll in the study. Understanding how different types of weight loss treatment impact pelvic floor symptoms will help clinicians guide which weight loss treatments are recommended for patients with pelvic floor symptoms in the future.",[28,459,460,301,461,462,463,464,465],"Stress Urinary Incontinence","Urge Urinary Incontinence","Pelvic Organ Prolapse","Weight Loss","Fecal Incontinence","Bariatric Surgery","glp1 Agonist",[467,468,469,470,471,472,473,474,475],"lower urinary tract symtpoms","stress urinary incontinence","urge urinary incontinence","overactive bladder","pelvic organ prolapse","weight loss","fecal incontinence","bariatric surgery","glp1 agonist","2025-09-15",{"date":478,"type":33},"2025-09-16",{"date":480,"type":21},"2025-10",{"date":482,"type":21},"2027-06",{"name":484,"class":40},"Hartford HealthCare",{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":41},"100529890","preoperative-pelvic-floor-physical-therapy-to-minimize-stress-urinary-incontinence-after-holmium-laser-enucleation-of-the-prostate-100529890","NCT06179654","Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate","Inclusion Criteria:\n\n1. Age: \\>=18 years of age\n2. Sex: male sex assigned at birth (needs to have a prostate)\n3. BMI: all BMI\n4. Ethnic background: all ethnicities\n5. Medical history: patients scheduled to undergo HoLEP for BPH\u002FLUTS and associated complications (i.e. gross hematuria, retention, etc.).\n\nExclusion Criteria:\n\n1. Neurological disorders: patients with a history of a neurologic disorder that could affect muscle function, neurogenic bladder, lumbosacral spine pathology\n2. Specific urologic conditions: patients with pre-operative indwelling catheter, urethral stricture greater than 1 centimeter in length or requiring dilation\u002Fincision, indwelling ureteral stent\n3. History of pelvic radiation: patient with prior pelvic radiation will be excluded\n4. Patients unable to give consent\n5. Non-English speaking patients given the need for multiple surveys and telephone follow-ups.",{"count":492,"type":21},36,[24],"The purpose of this study is to allow us to assess the effectiveness (or success) of starting pelvic floor physical therapy (i.e. exercises for your pelvic muscles) prior to HoLEP (holmium laser enucleation of the prostate) surgery for enlarged prostates in order to manage or prevent urinary incontinence (i.e. leaking) after surgery (i.e. post-operatively). Your pelvic floor refers to the muscles under your bladder along your pelvic bones that prevent you from leaking urine or stool. Traditionally, pelvic floor physical therapy is started after surgery and continued until urinary continence (i.e. no leaking of urine) is regained. We want to assess if beginning pelvic floor physical therapy prior to surgery (and continuing afterwards) reduces the time required to regain urinary continence following HoLEP.",[496,497,28],"Benign Prostatic Hyperplasia With Outflow Obstruction","Urinary Retention","2025-08-20",{"date":500,"type":33},"2025-08-21",{"date":502,"type":33},"2023-11-29",{"date":504,"type":21},"2026-10-31",{"name":506,"class":40},"The Cleveland Clinic",{"id":508,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":25,"conditions":511,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":515,"leadSponsor":516,"locationsCount":41},"100347369",{"count":20,"type":21},[24],[27,28],{"date":513,"type":33},"2025-08-27",{"date":35,"type":33},{"date":37,"type":21},{"name":39,"class":40},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":22,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":540},"100497472","evaluation-of-the-safety-tolerability-and-efficacy-of-the-omega-system-for-the-treatment-of-luts-due-to-bph-100497472","NCT05757687","Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH","Evaluation of the Safety, Tolerability and Efficacy the Omega System for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia","Omega","Stage 1\n\nInclusion Criteria:\n\n1. Male ≥50 years of age and ≤ 80 years old.\n2. Will undergo planned prostatectomy.\n3. Participant understands and is willing to the informed consent form.\n4. Prostate Volume between 30cc and 80cc.\n5. Prostate length ≥ 3cm\n\nExclusion Criteria:\n\n1. Unable to comply with the clinical protocol.\n2. Vulnerable population such as inmates or developmentally delayed individuals.\n3. Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure, such as:\n\n   * Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and\u002For antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy is not prohibited).\n   * Use of alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.\n   * Use of 5-α-reductase inhibitors within 6 months of pre-treatment (baseline) evaluation.\n4. American Society of Anesthesiologists score (ASA) \\> 3.\n5. Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.\n6. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.\n7. Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.\n8. Previous rectal surgery, other than hemorrhoidectomy\n9. Current gross hematuria.\n10. Known allergy to nickel or titanium or stainless steel.\n\nStage 2\n\nInclusion Criteria:\n\n1. Male ≥50 years old.\n2. Suspected symptomatic benign prostatic hyperplasia (BPH).\n3. International Prostate Symptom Score (IPSS) \\>13.\n4. Peak flow rate ≤ 12 ml\u002Fsec (with voided volume ≥ 125ml).\n5. Participant understands and is willing to the informed consent form.\n6. Prostate Volume between 30cc and 80cc.\n7. Prostate length ≥ 3cm and ≤ 5cm\n\nExclusion Criteria:\n\n1. Diagnosed or suspected prostate cancer. If suspected, prostate cancer must be ruled out.\n2. Concomitant participation in another interventional study.\n3. Unable to comply with the clinical protocol including all the follow-up requirements.\n4. Vulnerable population such as inmates or developmentally delayed individuals.\n5. Significant comorbidities which would affect study participation.\n6. Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure ,such as:\n\n   * Use of concomitant medications (e.g., anticholinergics, antispasmodics, or antidepressants) affecting bladder function.\n   * Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and\u002For antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure; low dose aspirin therapy not prohibited.\n   * Alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.\n   * Taking 5-alpha reductase inhibitors (5-ARI) within 6 months (3 months for type II 5-ARI) of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study).\n   * Patient is taking steroids. \\[Note: Patients approved for the trial who are using the above medications will continue using them after the trial, except for Alpha blockers.\\]\n7. Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.\n8. Compromised renal function due to obstructive uropathy.\n9. Active Urinary Tract Infection (UTI).\n10. Obstructive or protruding median lobe.\n11. American Society of Anesthesiologists score (ASA) \\> 3.\n12. Known neurogenic bladder or neurological disorders that might affect bladder or function.\n13. Recent myocardial infarction (less than three months).\n14. Concomitant bladder stones.\n15. Current gross hematuria.\n16. Active or history of epididymitis within the past 3 months.\n17. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.\n18. Confirmed or suspected malignancy of bladder.\n19. History or presence of strictures in the anterior urethra or bladder neck contracture or detrusor muscle spasms.\n20. Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.\n21. Bacterial prostatitis within the last 12 months.\n22. Previous rectal surgery, other than hemorrhoidectomy.\n23. Current uncontrolled diabetes (i.e., hemoglobin A1c ≥ 9%).\n24. Known allergy to nickel or titanium or stainless steel.",{"count":526,"type":21},11,[24],"This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety\u002Ftolerability\u002Fefficacy of the Omega System device. The Omega arc-shaped implant is inserted by the Omega delivery system into the prostate tissue of subjects to relieve lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The study will first evaluate the Omega system on patients undergoing prostatectomy, which is not indicated for the device.",[28,57],"2025-08-04",{"date":532,"type":33},"2025-08-07",{"date":534,"type":33},"2023-02-07",{"date":536,"type":21},"2026-09-01",{"name":538,"class":539},"ProArc Medical","INDUSTRY",5,{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":209},"100410683","omega-study-evaluation-of-the-safety-and-efficacy-of-the-omega-system-for-the-treatment-of-bph-100410683","NCT04627701","Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH","Evaluation of the Safety and Efficacy of the Omega System for the Treatment of Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n1. Male ≥50 years of age\n2. Diagnosed with symptomatic benign prostatic hyperplasia (BPH).\n3. International Prostate Symptom Score (IPSS) \\>13.\n4. Peak flow rate ≤ 12 ml\u002Fsec (with voided volume ≥ 125ml).\n5. Participant understands and is willing to the informed consent form.\n6. Prostate Volume between 30cc and 80cc.\n7. Prostate length ≥3cm and ≤5cm\n\nExclusion Criteria:\n\n1. Concomitant participation in another interventional study.\n2. Unable to comply with the clinical protocol including all the follow-up requirements.\n3. Vulnerable population such as inmates or developmentally delayed individuals.\n4. Significant comorbidities which would affect study participation.\n5. Diagnosed or suspected prostate cancer. If suspected, prostate cancer must be ruled out.\n6. Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure, such as:\n\n   * Use of concomitant medications (e.g., anticholinergics, antispasmodics, or antidepressants) affecting bladder function.\n   * Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and\u002For antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure; low dose aspirin therapy not prohibited.\n   * Alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.\n   * Taking 5-alpha reductase inhibitors (5-ARI) within 6 months (3 months for type II 5-ARI) of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study).\n   * Patient is taking steroids. \\[Note: Patients approved for the trial who are using the above medications will continue using them after the trial, except for Alpha blockers\\]\n7. Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.\n8. Compromised renal function due to obstructive uropathy.\n9. Active Urinary Tract Infection (UTI).\n10. Obstructive or protruding median lobe\n11. American Society of Anaesthesiologists score (ASA) \\> 3.\n12. Known neurogenic bladder or neurological disorders that might affect bladder or function.\n13. Recent myocardial infarction (less than three months).\n14. Concomitant bladder stones.\n15. Current gross hematuria.\n16. Active or history of epididymitis within the past 3 months.\n17. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.\n18. Confirmed or suspected malignancy of bladder.\n19. History or presence of strictures in the anterior urethra or bladder neck contracture or detrusor muscle spasms.\n20. Other Urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.\n21. Bacterial prostatitis within the last 12 months.\n22. Previous rectal surgery, other than hemorrhoidectomy.\n23. Current uncontrolled diabetes (i.e., hemoglobin A1c ≥ 9%).\n24. Known allergy to nickel or titanium or stainless steel.",{"count":173,"type":21},[24],"The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH. During the procedure an implant is delivered into the prostate tissue obstructing the urethra and restricting urine flow. The delivery system uses a static diathermy incision mechanism to make a circumferential incision in the tissue surrounding the prostatic urethra into which the Omega shaped permanent implant is placed. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.",[57,28],{"date":532,"type":33},{"date":554,"type":33},"2023-07-23",{"date":556,"type":21},"2026-08",{"name":538,"class":539},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":564,"maxAge":218,"enrollmentInfo":565,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":41},"100598166","prevalence-of-functional-lower-urinary-tract-voiding-dysfunction-in-school-aged-children-100598166","NCT07067957","Prevalence of Functional Lower Urinary Tract Voiding Dysfunction in School-Aged Children","Inclusion Criteria:\n\n* Children aged 4-14 years old in our locality.\n\nExclusion Criteria:\n\n* Children with known anatomical anomalies of urinary tract\n* Children with known neurological anomalies (spinal dysraphism, multiple sclerosis, lumbar or spinal neuritis……… etc)\n* Children with history of back or lower urinary tract trauma\n* Parents who refuse participation","4 Years",{"count":297,"type":21},"The aim of this study is to investigate the prevalence of voiding disorders and the related risk factors for the primary school-age children in El Ghrbia Government",[568,188,190,28,569,570],"Voiding Dysfunction","Pediatrics","Constipation","2025-07-06",{"date":573,"type":33},"2025-07-16",{"date":575,"type":21},"2025-07-10",{"date":577,"type":21},"2025-11-30",{"name":579,"class":40},"Tanta University",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":329,"maxAge":354,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":588,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":41},"100512634","phase-2-efficacy-of-tadalafil-5mg-for-treatment-of-early-storage-symptoms-and-erectile-dysfunction-after-endoscopic-enucleation-of-prostate-100512634","NCT05955001","Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate","A Randomized Controlled Trial to Examine the Utility of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Anatomical Endoscopic Enucleation of Prostate (AEEP)","Inclusion Criteria:\n\n* Patients' age ≥ 40 years\n* LUTS secondary to BOO due to BPH who failed medical treatment\n* International prostate symptom scores (IPSS) \\>15 and bother score (QOL) ≥ 3 (according to IPSS question 8)\n* Peak urinary flow rate (Qmax) \\\u003C15 ml\u002Fsec.\n* ASA (American society of anaesthesiologists) score ≤ 3.\n* Sexually active men, not receiving PDE5I\n\nExclusion Criteria:\n\n* Patients using nitrates, potassium channel opener, or α1-blockers doxazosin and terazosin for control of hypertension\n* Patients with unstable angina pectoris, recent myocardial infarction or stroke myocardial insufficiency.\n* Patients with severe hepatic or renal insufficiency.\n* Patients who are sexually inactive.\n* Patients with uncontrolled diabetes mellitus or neurologic condition(eg. parkinsoism)",{"count":185,"type":21},[130,589],"PHASE3","From previous studies, the investigators found that sexual outcomes after prostate surgery may show insignificant improvement, remain unchanged or deteriorate in non-negligible number of patients especially those with high preoperative IIEF scores. Deterioration of erectile function could be attributed to persistence of storage symptoms specially nocturia. Several pathophysiologic mechanisms, described before, are involved in pathogenesis of LUTS and ED and one can imagine that after relief of obstruction, the erectile function should improve, however lack of improvement or even deterioration suggests that damage associated with these mechanisms is irreversible and patients may require some sort of penile rehabilitation after surgery.\n\nThe investigators hypothesized that Tadalafil may enhance relief of storage symptoms and enhance recovery of erectile function after surgery for BPH. With this assumption, a RCT was designed to examine the utility and efficacy of Tadalafil, once daily dose, to relieve persistent\u002F de novo storage symptoms and early erectile function deterioration after endoscopic prostate surgery.",[592,28],"Erectile Dysfunction","2025-06-06",{"date":595,"type":33},"2025-06-11",{"date":597,"type":33},"2023-04-01",{"date":599,"type":21},"2025-07",{"name":346,"class":40},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":181,"sex":453,"minAge":183,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":4},"100589636","lower-urinary-tract-symptoms-in-transmasculine-patients-undergoing-metoidioplasty-and-their-acceptability-of-pelvic-floor-muscle-training-assessed-by-a-pelvic-obstetric-and-gynaecological-physiotherapist-100589636","NCT06956989","Lower Urinary Tract Symptoms in Transmasculine Patients Undergoing Metoidioplasty and Their Acceptability of Pelvic Floor Muscle Training Assessed by a Pelvic, Obstetric and Gynaecological Physiotherapist","LUTS-POGP","Inclusion Criteria:\n\nHave capacity to consent.\n\nDiagnosis of gender dysphoria and have lived in a gender role that is congruent to their gender identity for minimum of 12 months.\n\nTransmasculine patients referred to CCGS for masculinising lower genital reconstructive surgery having received two signatures confirming suitability for reconstructive surgery.\n\nUndergoing metoidioplasty\u002Fphalloplasty.\n\nAge \\>17 years old.\n\nOn systemic testosterone therapy for more than 12 months.\n\nExclusion Criteria:\n\n* Age less than 18 years.\n\nNot undergoing metoidioplasty\u002Fphalloplasty.",{"count":609,"type":21},50,"Lower urinary tract symptoms in transmasculine patients undergoing metoidioplasty and their acceptability of pelvic floor muscle training assessed by a Pelvic, Obstetric and Gynaecological Physiotherapist.\n\nStudy Design\n\nProspective observational pilot study\n\nStudy Participants\n\nTransmasculine patients undergoing metoidioplasty\n\nPlanned Sample Size\n\n50\n\nPlanned Study Period\n\n2025\u002F26\n\nObjectives\n\nUnderstand the acceptability of first-line pelvic floor muscle training (PFMT) treatment in transmasculine patients undergoing metoidioplasty\n\nBackground incidence of lower urinary tract symptoms (LUTS) in transmasculine patients undergoing surgery\n\nEndpoints\n\nAcceptability of PFMT questionnaire\n\nInternational Prostate Symptom Score (I-PSS) and International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) questionnaires and uroflowmetry",[28,612],"Transgenderism","2025-04-25",{"date":615,"type":33},"2025-05-04",{"date":617,"type":21},"2025-08",{"date":619,"type":21},"2027-08",{"name":621,"class":40},"Chelsea and Westminster NHS Foundation Trust",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":50,"minAge":126,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":22,"phases":631,"briefSummary":632,"conditions":633,"keywords":634,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":649,"locationsCount":651},"100533412","prescription-exercise-for-older-men-with-urinary-disease-100533412","NCT06225479","PRescription Exercise for Older Men With Urinary Disease","PRescription Exercise for Older Men With Urinary Disease (PROUD) Pilot Study","PROUD","Inclusion Criteria:\n\n1. Age 60 years or older.\n2. Male sex at birth.\n3. Moderate-to-severe LUTS over the past month (defined as International Prostate Symptom Score \\[IPSS\\] \\>=12).\n4. A clinical diagnosis of LUTS\u002FBPH as demonstrated by a current or prior BPH medication prescription (alpha-blocker, 5alpha-reductase inhibitor, daily phosphodiesterase type 5 inhibitor) OR untreated LUTS\u002FBPH and a maximum urinary flow rate \\\u003C=12 ml\u002Fsec.\n5. Physically inactive as defined in the Molecular Transducers of Physical Activity Consortium (MoTrPAC): no more than 1 day per week, lasting no more than 60 minutes, of regular endurance\u002Faerobic exercise \\[e.g., brisk walking, jogging, running, cycling, elliptical, or swimming activity that results in feelings of increased heart rate (HR), rapid breathing, and\u002For sweating\\] or resistance exercise \\[resulting in muscular fatigue\\] in the past year). Leisure walkers are eligible unless they meet the HR, breathing, and sweating criteria.\n6. Able to walk 400m without sitting, leaning, or the help of another person (observed during exercise testing) to ensure safety while exercising with remote monitoring. Use of a straight cane is allowed.\n7. Able to speak and complete questionnaires in English.\n8. Have an iOS or Android smartphone capable of installing the Polar Beat app.\n\nExclusion Criteria:\n\n1. Prescribed overactive bladder medications (e.g., anti-muscarinics, beta-3-adrenergic agonists) \\\u003C3 months before screening.\n2. Initiation, dose escalation, or weaning of BPH medications \\\u003C1 month before screening (\\\u003C6 months for 5-alpha-reductase inhibitors). Participants' must also be willing to not start, stop, or change their BPH medications for the subsequent 7 months (the entire study period).\n3. Initiation, dose escalation, or weaning of other pharmacologic agents or dietary supplements that might affect LUTS (e.g., saw palmetto, testosterone, diuretics, glucose-lowering agents) \\\u003C1 month before screening. Participants' must also be willing to not start, stop, or change these medications for the subsequent 7 months (the entire study period) unless deemed necessary by their clinician.\n4. History of BPH procedure or surgery.\n5. History of overactive bladder procedure (e.g., intravesical Botox, sacral neuromodulation, posterior tibial nerve stimulation).\n6. History of prostate cancer (treated with surgery or radiation), bladder cancer, other lower urinary tract cancer, pelvic radiation, or active non-urologic cancer treatments.\n7. History of urethral strictures.\n8. History of neurogenic bladder or neurologic conditions causing lower urinary tract dysfunction (e.g., Parkinson's disease, multiple sclerosis, other progressive neurological disease).\n9. History of recurrent bladder or prostate infections (3 or more infections in the previous 12 months before screening).\n10. History of severe or end-stage chronic kidney disease disease, kidney transplant, heart transplant, congenital heart disease, severe heart failure (defined as current New York Heart Association (NYHA) Class III or IV), valvular heart disease, diabetic coma, or the presence of a pacemaker or implantable cardiac defibrillator without clinician clearance.\n11. Heart attack or myocardial infarction, heart surgery, cardiac catheterization, stroke, transient ischemic attack, brain hemorrhage, bleeding brain aneurysm, blood clot in leg or lungs, symptomatic hypoglycemia or hyperglycemia, hip fracture, or non-elective hospitalization \\\u003C6 months before screening. If conditions occurred 6 to \\\u003C12 months before screening, can participate with clinician clearance.\n12. Bladder or prostate infection \\\u003C1 months before screening. If infection occurred between 1 to \\\u003C3 months before screening, can participate with clinician clearance.\n13. Major surgery \\\u003C3 months before screening or scheduled in the subsequent 7 months.\n14. Terminal illness diagnosis with estimated life expectancy \\\u003C12 months.\n15. Plan to leave the study area for \\>28 consecutive days during the subsequent 7 months.\n16. Participation in formal behavioral LUTS interventions (e.g., pelvic floor physiotherapy) \\\u003C1 month before screening.\n17. Symptoms of possible coronary artery disease, heart failure, arrythmia, stroke, carotid artery stenosis, valvular heart disease, blood clot in lungs, poorly controlled diabetes, peripheral vascular disease, or bladder or prostate infection without clinician clearance.\n18. Maximum urinary flow rate \\\u003C=4 ml\u002Fsec OR volume voided during free flow \\\u003C120ml during screening or the baseline visit.\n19. Post-void residual \\>=450ml measured by ultrasound during screening or the baseline visit.\n20. Uncontrolled hypertension (systolic blood pressure \\>180mmHg or diastolic blood pressure \\>110mmHg) or hypotension (systolic blood pressure\\\u003C100mmHg) measured during baseline visit anthropometric assessments.\n21. Severe abnormalities on standard clinical labs measured prior to the baseline visit, without clinician clearance, including hemoglobin A1c (\\>10%) and urinary albumin: creatinine ratio (\\>300 mg\u002Fg).\n22. Other medical, psychiatric, or behavioral factors or participation in other research studies that, based on the judgment of the multiple principal investigators, may interfere with study participation, assessments, or the ability to follow either the exercise intervention or the health education control.\n23. Use of a permanent or temporary urinary catheter.",{"count":379,"type":21},[24],"This is a single-center pilot randomized controlled trial among 68 physically \"inactive\" older men with lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (LUTS\u002FBPH) assessing a 12-week remote exercise intervention versus health education control.",[28,57],[635,636,637,638,639,640,641,642],"physical fitness","endurance training","resistance training","prostatism","male urogenital diseases","urinary bladder outlet obstruction","skeletal muscle","mitochondria","2025-03-13",{"date":645,"type":33},"2025-03-17",{"date":647,"type":33},"2024-01-03",{"date":283,"type":21},{"name":650,"class":40},"University of California, San Francisco",2]